Search Results

Long-Term Results of TAXUS ATLAS Clinical Program Presented

September 22, 2010—Boston Scientific Corporation (Natick, MA) announced that coprincipal investigators Mark A. Turco, MD, and John A. Ormiston, MD, presented comprehensive data from the TAXUS ATLAS clinical program at the Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC. The TAXUS ATLAS program is a series of global, prospective, single-arm trials evaluating the company's Taxus Liberté paclitaxel-eluting stent system in a variety of lesions and patient groups.

Two-Year Follow-Up Data for MiStent SES Presented

October 28, 2013—Micell Technologies, Inc. (Durham, NC) announced the presentation of imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of the MiStent SES, the company's sirolimus-eluting, absorbable polymer coronary stent system.

Micell Technologies Presents 3-Year Data From DESSOLVE Trials

September 16, 2014—Micell Technologies, Inc. announced 3-year clinical results from the DESSOLVE I and DESSOLVE II trials of the company’s MiStent SES, a sirolimus-eluting absorbable polymer coronary stent system.  John Ormiston, MD, who serves as a Principal Investigator in the DESSOLVE studies, presented the data at the 26th Transcatheter Cardiovascular Therapeutics Conference in Washington, DC.

Two-Year Data Published for DESSOLVE Trials of Micell's MiStent

October 5, 2015—Two-year outcomes from the DESSOLVE I and DESSOLVE II trials of the bioabsorbable polymer-coated, sirolimus-eluting coronary MiStent (Micell Technologies, Inc.) were published by William Wijns, MD, et al online ahead of print in EuroIntervention.  DESSOLVE I is the first-in-human clinical assessment of safety and efficacy of the MiStent and included 30 patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23-mm-length stent.

Micell's MiStent Supported by Published DESSOLVE I Results

September 18, 2013—John Ormiston, MD, et al published imaging and clinical results of the DESSOLVE I trial of the MiStent (Micell Technologies, Inc., Durham, NC) in the treatment of patients with de novo lesions in the native coronary arteries.

Abbott Vascular Presents ABSORB Trial Data

September 22, 2010—Abbott Vascular (Santa Clara, CA) announced that the results from the first 45 patients enrolled in the second stage of the ABSORB trial were presented by coprincipal investigator John Ormiston, MD, presented at the annual Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC.

Volcano Introduces Vibe RX Vascular Imaging Balloon Catheter

May 26, 2010—Volcano Corporation (San Diego, CA) announced that it has received CE Mark approval for the Vibe RX vascular imaging balloon catheter.

Boston Scientific's Promus Premier Drug-Eluting Stent Receives CE Mark Approval

February 12, 2013—Boston Scientific Corporation (Natick, MA) announced that it has received CE Mark approval for the Promus Premier everolimus-eluting platinum-chromium (PtCr) coronary stent system, the company's next-generation durable-polymer drug-eluting stent (DES) technology.

Boston Scientific Presents Data Supporting Promus Premier and Synergy DES

May 22, 2013—At EuroPCR 2013 in Paris, Boston Scientific Corporation (Natick, MA) reported positive results from the NG PROMUS and the EVOLVE trials, which are evaluating new drug-eluting stent (DES) technologies for the treatment of coronary heart disease.

FDA Approves Boston Scientific's Promus Premier DES

November 25, 2013—Boston Scientific Corporation (Natick, MA) announced US Food and Drug Administration (FDA) approval for the Promus Premier everolimus-eluting platinum chromium coronary stent system, the company's next-generation durable polymer drug-eluting stent (DES). The company received European CE Mark approval for the Promus Premier stent system in February 2013.